315,160 Shares in Bioventus Inc. $BVS Purchased by Meros Investment Management LP

Meros Investment Management LP purchased a new position in Bioventus Inc. (NASDAQ:BVS) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 315,160 shares of the company’s stock, valued at approximately $2,345,000. Meros Investment Management LP owned 0.38% of Bioventus at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC increased its stake in Bioventus by 4.1% in the 4th quarter. Nantahala Capital Management LLC now owns 6,047,403 shares of the company’s stock worth $44,993,000 after buying an additional 236,741 shares during the period. Vanguard Group Inc. increased its stake in Bioventus by 4.4% in the 3rd quarter. Vanguard Group Inc. now owns 2,924,788 shares of the company’s stock worth $19,567,000 after buying an additional 122,749 shares during the period. Royce & Associates LP increased its stake in Bioventus by 15.6% in the 3rd quarter. Royce & Associates LP now owns 1,262,976 shares of the company’s stock worth $8,449,000 after buying an additional 170,900 shares during the period. Geode Capital Management LLC increased its stake in Bioventus by 1.8% in the 4th quarter. Geode Capital Management LLC now owns 1,120,238 shares of the company’s stock worth $8,337,000 after buying an additional 19,388 shares during the period. Finally, State Street Corp increased its stake in Bioventus by 1.7% in the 4th quarter. State Street Corp now owns 891,024 shares of the company’s stock worth $6,629,000 after buying an additional 14,590 shares during the period. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Bioventus in a research report on Tuesday, June 2nd. Craig Hallum raised their target price on shares of Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Barrington Research reissued an “outperform” rating and set a $14.00 target price on shares of Bioventus in a research report on Friday, May 22nd. Cantor Fitzgerald raised shares of Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th. Finally, CJS Securities assumed coverage on shares of Bioventus in a research report on Friday, March 27th. They set a “market outperform” rating and a $14.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $14.00.

Bioventus Stock Up 1.1%

NASDAQ:BVS opened at $8.60 on Tuesday. Bioventus Inc. has a fifty-two week low of $5.81 and a fifty-two week high of $11.25. The stock has a market capitalization of $718.44 million, a P/E ratio of 20.98, a P/E/G ratio of 1.10 and a beta of 0.67. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.13 and a current ratio of 1.69. The company’s 50-day simple moving average is $9.59 and its 200-day simple moving average is $8.65.

Bioventus (NASDAQ:BVS) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.06. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. The business had revenue of $132.09 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, equities analysts anticipate that Bioventus Inc. will post 0.77 earnings per share for the current fiscal year.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non?surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low?intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.